BioCatalyst

TNG260, Pembrolizumab — catalyst calendar

1 verified catalyst event(s) referencing TNG260, Pembrolizumab, each linked to its official source. Verified as of 2026-08-06.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-09 (month)
in 26d
ESTIMATED
 READOUT
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Phase 1/2 · Non Small Cell Lung Cancer, Solid Tumors, Adult
 TNGX Tango Therapeutics, Inc. TNG260, Pembrolizumab ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.